top of page
A framework to support new product introduction in national health systems
Resource Library


pALD Posters for Health Facilities and Caregivers
CHAI has developed two new posters to support the introduction of pediatric Abacavir/Lamivudine/Dolutegravir (pALD) in health systems....
Jul 7
Â
Â


2024 HIV Market Report
CHAI is pleased to release the fifteenth issue of our annual HIV market report. The 2024 HIV Market Report provides a detailed look at...
Dec 4, 2024
Â
Â


2024 HIV Mid-Year Market Memo
Introducing the eighth edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...
Jul 17, 2024
Â
Â


Planning Considerations for the Introduction of pALD
This slide deck, presented by CHAI at IPHASA 2023, outlines planning considerations for the introduction of pALD throughout all stages of...
Dec 14, 2023
Â
Â


2023 HIV Market Report
CHAI is pleased to release the fourteenth issue of our annual HIV market report. This report provides a detailed look at the complex,...
Nov 1, 2023
Â
Â


Pediatric Treatment Optimization Roadmap
This treatment optimization roadmap is a resource for Ministries of Health and partner organizations. It offers a summary of pediatric...
Oct 20, 2023
Â
Â


Pediatric DRV/r (pDRV/r) FAQs
This document is meant to answer some of the most common questions that surround pediatric darunavir/ritonavir 120/20mg (pDRV/r) - a new...
Sep 6, 2023
Â
Â


Pediatric DRV/r (pDRV/r) Product Profile
This product profile provides a clinical overview of the best-in-class protease inhibitor (PI) formulated in a fixed-dose combination...
Sep 6, 2023
Â
Â


2023 CHAI HIV Mid-Year Market Memo
Introducing the seventh edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...
Jun 7, 2023
Â
Â


Pediatric ALD (pALD) FAQs
This document is meant to answer some of the most common questions surround the fixed-dose combination of pediatric...
Jun 5, 2023
Â
Â


pALD Product Profile
This product profile provides a clinical overview of the fixed-dose combination of pediatric abacavir/lamivudine/ dolutegravir 60/30/5 mg...
May 30, 2023
Â
Â


GAP-f pALD Introduction and Rollout Planning Considerations for National Programmes
The GAP-f pDTG task team has developed a brief outlining product introduction and rollout considerations for national programmes when...
May 24, 2023
Â
Â


The Transitioning Children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study
The Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study was conducted in Benin, Nigeria, and Uganda....
May 4, 2023
Â
Â


2022 HIV Market Report
CHAI is pleased to release the 13th issue of our annual HIV market report. This report provides a detailed look at the complex,...
Dec 16, 2022
Â
Â


2022 CHAI HIV Mid-Year Market Memo
Introducing the sixth edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...
May 31, 2022
Â
Â


GAP-f pDTG Implementation Considerations for National Programmes
In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 ...
May 24, 2022
Â
Â


Adult DRV/r (400/50mg) FAQs for Communities and PLHIV
CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...
Apr 13, 2022
Â
Â


Adult DRV/r (400/50mg) Clinical Action Memo
Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...
Mar 17, 2022
Â
Â


CHAI DRV/r 2L Product Profile
A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.
Mar 17, 2022
Â
Â


DRV/r (400/50mg) FAQs
CHAI developed these frequently asked questions (FAQs) to lay out information for national HIV programs considering the adoption and...
Mar 17, 2022
Â
Â
bottom of page